GSK Entered into an Exclusive Licence Agreement and SCYNEXIS to Develop and Commercialise Brexafemme (ibrexafungerp) for Fungal In...
Shots: SCYNEXIS to receive $90M up front, $503M in milestones incl. ~$70M in regul...
Confo Therapeutics Entered into a Collaboration Agreement with Daiichi Sankyo to Discover Novel Therapies for Central Nervous Syst...
Shots: Confo to receive up front & is eligible to receive development and comm...
Théa Open Innovation Signs a License Agreement with Galimedix to Develop and Commercialize GAL-101 for Ophthalmic Indications
Shots: Galimedix will receive an up front technology access fee, success-based mil...
Covant Entered into an Exclusive Research Collaboration and Worldwide License Agreement with Boehringer Ingelheim to Develop Cance...
Shots: Covant to receive $10M up front and will be eligible for ~$471M in addition...
Bicycle Therapeutics Signs a Collaboration Agreement with Novartis to Develop and Commercialize Multiple Targeted Bicycle Radio-Co...
Shots: Bicycle to receive a $50M up front, ~$1.7B in development & commercial-...
OncoVent, a Subsidiary of Hepalink and Orient EuroPharma Enters into a License and Distribution Agreement to Develop and Commercia...
Shots: OncoVent to receive a total transaction amount of $11.2M incl. a one-off no...
